Long-term outcomes of alemtuzumab in relapsing–remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab

Journal of the Neurological Sciences · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles